These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 21157106)

  • 1. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW; Kang SJ; Ahn JM; Song HG; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2012 Jun; 109(12):1700-4. PubMed ID: 22440123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):1013-22. PubMed ID: 25240453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
    Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
    Stegman B; Puri R; Cho L; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nissen SE; Nicholls SJ
    Diabetes Care; 2014 Nov; 37(11):3114-20. PubMed ID: 25190674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
    Betteridge DJ; Gibson JM; Sager PT
    Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound.
    Han SH; Chung WJ; Kang WC; Lee K; Park YM; Shin MS; Ahn TH; Choi IS; Shin EK
    Int J Cardiol; 2012 Jul; 158(2):217-24. PubMed ID: 21295363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
    Mintz GS
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):378-9. PubMed ID: 24448226
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day.
    Hong YJ; Jeong MH; Choi YH; Ma EH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Youn HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Am J Cardiol; 2010 Nov; 106(9):1241-7. PubMed ID: 21029819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
    Bullano MF; Kamat S; Wertz DA; Borok GM; Gandhi SK; McDonough KL; Willey VJ
    Am J Health Syst Pharm; 2007 Feb; 64(3):276-84. PubMed ID: 17244877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.